贝达药业高管：已上市创新药全部适应症均纳入国家医保目录

Core Viewpoint - Beida Pharmaceutical Co., Ltd. announced that four of its innovative drugs have been included in the National Medical Insurance Directory for 2025, reflecting the recognition of the company's innovation capabilities and the clinical value of its drugs by the national medical insurance department [1][5]. Group 1: Drug Information - The four drugs included are: 1. Erlotinib Hydrochloride Tablets - the first domestically developed EGFR-TKI for lung cancer treatment with independent intellectual property rights [1]. 2. Ensartinib Capsules - a new generation ALK inhibitor co-developed with Xcovery [1]. 3. Befotnib - a third-generation EGFR-TKI and a national class 1 innovative drug with independent intellectual property rights [2]. 4. Vorolanib Tablets - a new multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and is used for treating pathological angiogenesis diseases [2]. Group 2: Impact on Business - Inclusion in the National Medical Insurance Directory is expected to enhance the accessibility of these products and positively impact sales [5]. - The directory will be effective from January 1, 2026, and the immediate impact on the company's operating performance cannot be accurately estimated at this time [5].